BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.
| Website | http://biogenix.com |
| Revenue | $7.8 million |
| Employees | 52 (14 on RocketReach) |
| Founded | 2011 |
| Technologies |
JavaScript
,
HTML
,
jQuery
+7 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Regenerative Medicine, Cell Therapy, Tissue Regeneration, Stem Cell Therapy, Regenerative Therapies, Wound Healing, Chronic Disease Treatment, Degenerative Disease Treatment, Biologics, Biotechnology, Pharmaceutical Research, Drug Discovery, Medical Innovation, Healthcare Solutions, Advanced Therapies, Innovative Treatments, Patient Care, Clinical Trials, Medical Research, Therapeutic Solutions |
| Competitors | Novo Nordisk, Genentech, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Illumina, Moderna Therapeutics, Sangamo Therapeutics, Inc., Lilly India +46 more (view full list) |
Looking for a particular BioGenix employee's phone or email?
The BioGenix annual revenue was $7.8 million in 2026.
Michael Stavitski is the President South East Asia of BioGenix.
14 people are employed at BioGenix.